Results 181 to 190 of about 843,559 (297)

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

open access: yesThe FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén   +11 more
wiley   +1 more source

A novel therapeutic monoclonal antibody targeting PZR demonstrates potent anti-metastatic efficacy in triple-negative breast cancer. [PDF]

open access: yesJ Transl Med
Chen J   +12 more
europepmc   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

open access: yesHaemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita   +2 more
wiley   +1 more source

Chronic Spontaneous Urticaria Endotypes: Exploratory Proteomic Analysis in the Benralizumab ARROYO Study

open access: yes
Clinical &Experimental Allergy, EarlyView.
Eva Rodríguez‐Suárez   +10 more
wiley   +1 more source

Protective and Pathogenic Antibodies to Citrullinated Antigens. [PDF]

open access: yesImmunol Rev
Sareila O   +5 more
europepmc   +1 more source

Allergen‐Sensitised Whole Blood Samples for Quality Control and Benchmarking of Basophil Activation Tests

open access: yes
Clinical &Experimental Allergy, EarlyView.
Léonard Bezinge   +8 more
wiley   +1 more source

Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical Setting

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Emicizumab is a bispecific antibody approved for prophylaxis in people with haemophilia A (PwHA). Aim To describe from the physician perspective the characteristics and treatment experiences of PwHA receiving emicizumab. Methods The Adelphi Real World Haemophilia Disease Specific Programme is a cross‐sectional, retrospective data ...
Michael Recht   +7 more
wiley   +1 more source

FXI and FXII in experimental stroke and FXI in clinical stroke trials. [PDF]

open access: yesNeurol Res Pract
Mencl S   +5 more
europepmc   +1 more source

Patient Perspectives in Haemophilia A: Unmet Needs of Individuals Receiving Factor and Non‐Factor Treatments

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction There is limited qualitative published real‐world data on treatment patterns among people with severe haemophilia A (PwSHA), particularly those with unmet needs. Aim This qualitative study aimed to explore the impact of taking prophylactic extended half‐life factor VIII (EHL‐FVIII) or emicizumab on psychosocial and physical ...
Nana Kragh   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy